×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
PTN – palatin technologies, inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
PTN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/19
07:35 am
ptn
Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy [Yahoo! Finance]
Medium
Report
Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy [Yahoo! Finance]
12/19
07:30 am
ptn
Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy
High
Report
Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy
12/16
07:47 am
ptn
Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds [Yahoo! Finance]
Medium
Report
Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds [Yahoo! Finance]
12/16
07:30 am
ptn
Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds
Medium
Report
Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds
11/25
07:33 am
ptn
Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis [Yahoo! Finance]
High
Report
Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis [Yahoo! Finance]
11/25
07:30 am
ptn
Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis
High
Report
Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis
11/15
02:34 am
ptn
Palatin Technologies Inc (PTN) Q1 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue ... [Yahoo! Finance]
High
Report
Palatin Technologies Inc (PTN) Q1 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue ... [Yahoo! Finance]
11/14
07:39 am
ptn
Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results [Yahoo! Finance]
High
Report
Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/14/2024
07:30 am
ptn
palatin technologies, inc.
BEAT
Report
-10.8%
palatin technologies, inc.
5/15/2024
07:30 am
ptn
palatin technologies, inc.
BEAT
Report
-13.4%
palatin technologies, inc.
2/14/2024
04:17 pm
ptn
palatin technologies, inc.
MISS
Report
-23.2%
palatin technologies, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/16
09:25 am
ptn
Form 8-K PALATIN TECHNOLOGIES For: Dec 13
Medium
Report
Form 8-K PALATIN TECHNOLOGIES For: Dec 13
11/14
09:07 am
ptn
Form 10-Q PALATIN TECHNOLOGIES For: Sep 30
Medium
Report
Form 10-Q PALATIN TECHNOLOGIES For: Sep 30
11/14
09:01 am
ptn
Form 8-K PALATIN TECHNOLOGIES For: Nov 14
Medium
Report
Form 8-K PALATIN TECHNOLOGIES For: Nov 14
10/30
09:07 am
ptn
Form 424B3 PALATIN TECHNOLOGIES
Medium
Report
Form 424B3 PALATIN TECHNOLOGIES
10/30
06:02 am
ptn
Form EFFECT PALATIN TECHNOLOGIES
Medium
Report
Form EFFECT PALATIN TECHNOLOGIES
10/22
04:31 pm
ptn
Form S-1/A PALATIN TECHNOLOGIES
Low
Report
Form S-1/A PALATIN TECHNOLOGIES
10/7
04:31 pm
ptn
Form 8-K PALATIN TECHNOLOGIES For: Oct 04
Low
Report
Form 8-K PALATIN TECHNOLOGIES For: Oct 04
10/1
08:15 am
ptn
Form 8-K PALATIN TECHNOLOGIES For: Oct 01
Medium
Report
Form 8-K PALATIN TECHNOLOGIES For: Oct 01
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
8/6
Palatin Technologies To Present At Canaccord Genuity's 39th Annual Growth Conference
19.5%
6/26 Form 4 PALATIN TECHNOLOGIES For: Jun 24 Filed by: Rossetti Angela 11.0%
9/12 Form 10-K PALATIN TECHNOLOGIES For: Jun 30 6.0%
5/9 Form 10-Q PALATIN TECHNOLOGIES For: Mar 31 5.3%
5/9 Palatin Technologies' (PTN) CEO Carl Spana on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.2%
6/20 Form 8-K PALATIN TECHNOLOGIES For: Jun 20 3.9%
2/5 Form SC 13G/A PALATIN TECHNOLOGIES Filed by: BlackRock Inc. 2.6%
5/11 Palatin Technologies, Inc. (NASDAQ: PTN) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. 2.1%
11/7 Palatin Technologies, Inc. to Report First Quarter Fiscal Year 2020 Results; Teleconference and Webcast to be held on November 13, 2019 2.0%
8/7 Form 4 PALATIN TECHNOLOGIES For: Aug 05 Filed by: Hull Joseph Stanley 1.8%
6/26 Form 4 PALATIN TECHNOLOGIES For: Jun 24 Filed by: Rossetti Angela 11.0%
9/12 Form 10-K PALATIN TECHNOLOGIES For: Jun 30 6.0%
5/9 Form 10-Q PALATIN TECHNOLOGIES For: Mar 31 5.3%
5/9 Palatin Technologies' (PTN) CEO Carl Spana on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.2%
6/20 Form 8-K PALATIN TECHNOLOGIES For: Jun 20 3.9%
2/5 Form SC 13G/A PALATIN TECHNOLOGIES Filed by: BlackRock Inc. 2.6%
5/11 Palatin Technologies, Inc. (NASDAQ: PTN) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. 2.1%
11/7 Palatin Technologies, Inc. to Report First Quarter Fiscal Year 2020 Results; Teleconference and Webcast to be held on November 13, 2019 2.0%
8/7 Form 4 PALATIN TECHNOLOGIES For: Aug 05 Filed by: Hull Joseph Stanley 1.8%
TOP News Decliners
6/21
FDA approves drug for loss of sexual desire in women [Reuters (UK)]
-39.2%
2/10 Q2/2020 12/31/2019 EPS -0.020 ZacksConsensus 0.000 ActVsEst (0.020) - Miss -15.7%
4/30 Form PRE 14A PALATIN TECHNOLOGIES For: Jun 25 -9.8%
6/6 Palatin Technologies Granted FDA Orphan Drug Designation -- PL-8177 for the Treatment of Non-Infectious Uveitis -9.3%
7/1 Palatin Technologies Provides Mid-Calendar Year Corporate Update -8.4%
4/30 Palatin Technologies Provides Assessment of Impact of COVID-19 Pandemic on Business Operations -7.7%
9/12 Palatin Tech up 7% premarket on FY 2019 results [Seeking Alpha] -4.8%
2/6 Palatin Technologies, Inc. to Report Second Quarter Fiscal Year 2020 Results; Teleconference and Webcast to be held on February 11, 2020 -3.4%
11/1 Does Palatin Technologies (NYSEMKT:PTN) Deserve A Spot On Your Watchlist? [Yahoo! Finance News] -3.3%
9/11 Palatin Technologies, Inc. to Report Fourth Quarter & Fiscal Year End 2019 Results; Teleconference and Webcast to be held on September 12, 2019 -3.1%
2/10 Q2/2020 12/31/2019 EPS -0.020 ZacksConsensus 0.000 ActVsEst (0.020) - Miss -15.7%
4/30 Form PRE 14A PALATIN TECHNOLOGIES For: Jun 25 -9.8%
6/6 Palatin Technologies Granted FDA Orphan Drug Designation -- PL-8177 for the Treatment of Non-Infectious Uveitis -9.3%
7/1 Palatin Technologies Provides Mid-Calendar Year Corporate Update -8.4%
4/30 Palatin Technologies Provides Assessment of Impact of COVID-19 Pandemic on Business Operations -7.7%
9/12 Palatin Tech up 7% premarket on FY 2019 results [Seeking Alpha] -4.8%
2/6 Palatin Technologies, Inc. to Report Second Quarter Fiscal Year 2020 Results; Teleconference and Webcast to be held on February 11, 2020 -3.4%
11/1 Does Palatin Technologies (NYSEMKT:PTN) Deserve A Spot On Your Watchlist? [Yahoo! Finance News] -3.3%
9/11 Palatin Technologies, Inc. to Report Fourth Quarter & Fiscal Year End 2019 Results; Teleconference and Webcast to be held on September 12, 2019 -3.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: